EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting

Haoyue Zhou, Jinmei Li, Song Mei, Meiyu Zhang, Haochen Zhao, Kepeng Yan, Yumeng Cheng, Qunmin Zhou, Pan Zheng, Yang Liu, Peng Zhang, Hecheng Li und 2 weitere

Journal for ImmunoTherapy of Cancer · 2026-02 · 14 (2) · e013636

DOI: 10.1136/jitc-2025-013636 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, online erschienen am 24.02.2026. Verfasst von Haoyue Zhou und 13 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, T-Lymphocytes, Regulatory, Antigens, Differentiation, T-Lymphocyte, Immunotherapy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Project of MOST, China, Natural Science Foundation of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Global clinical programs based on TIGIT (T cell immunoglobulin and ITIM domain) blockade have been terminated due to inadequate clinical efficacy. New approaches are needed to increase the antitumor activity of anti-TIGIT-based immunotherapy.

Methods

Multiomics analyses, including single-cell RNA sequencing (scRNA-seq), single-cell TCR sequencing (scTCR-seq), and The Cancer Genome Atlas bulk RNA-seq, were performed to profile TIGIT and the costimulator CD226 expression and assess intratumoral regulatory T cells (Tregs) clonality, with validation by flow cytometry in murine and patient-derived tumor-infiltrating lymphocytes. The therapeutic efficacy of anti-TIGIT antibodies (αTIGIT), including αTIGIT-IgG1-wild-type (WT), αTIGIT-IgG1-WT with enhanced antibody-dependent cellular cytotoxicity (ADCC) activity (αTIGIT-IgG1-ADCC), αTIGIT-IgG4-WT, and tiragolumab, was evaluated in MC38 tumors-inoculated humanized TIGIT knock-in mice ( Tigit h/h , Tigit h/m ). Tumor microenvironment alterations were analyzed using flow cytometry and scRNA/TCR-seq. Antibody binding affinity and ADCC activity were assessed via biolayer interferometry and in vitro ADCC assays. Safety profiles were examined in a murine immune-related adverse events model through growth monitoring, survival analysis, and histopathological evaluation.

Results

Using mouse models and clinical sample analysis, we identified a population of TIGIT high CD226 − clonally expanded intratumoral Tregs as a major barrier limiting the ability of TIGIT blockade to enhance effector cell function. αTIGIT-IgG1-ADCC specifically targeted and eliminated the TIGIT high CD226 − clonally expanded Treg subset, resulting in a marked improvement in antitumor efficacy compared with WT and clinically unsuccessful αTIGIT. Mechanistically, removal of these Tregs through αTIGIT-IgG1-ADCC relieved their suppression of stem-like CD4 + T cells, facilitating their differentiation into T helper cell 1 (Th1) effector cells. Th1-derived interferon-gamma (IFN-γ) further enhanced the functionality of tumor-infiltrating CD8 + T cells. Importantly, the presence of clonally expanded intratumoral Tregs and the suppression of stem-like CD4 + T cells correlated with poor immunotherapy response in patients with non-small cell lung cancer.

Conclusions

Targeted elimination of clonally expanded intratumoral Tregs is essential to unlock the full therapeutic potential of αTIGIT. These novel findings provide a key rationale and strategic direction for overcoming the limitations of current αTIGIT-based cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Receptors, ImmunologicT-Lymphocytes, RegulatoryAntigens, Differentiation, T-LymphocyteImmunotherapyAnimalsHumansMiceT Lineage-Specific Activation Antigen 1Female

Stichwörter der Autor:innen

AntibodyImmune Checkpoint InhibitorImmune related adverse event - irAEImmunotherapyT regulatory cell - Treg

Substanzen

Receptors, ImmunologicT Lineage-Specific Activation Antigen 1TIGIT protein, humanAntigens, Differentiation, T-Lymphocyte

Autor:innen und Institutionen

  • Shanghai Institute of Immunology, Department of Immunology and Microbiology, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • AcroImmune Biopharmaceutical, Nanjing, China.
  • OncoC4, Rockville, Maryland, USA.
  • Beijing Pediatric Research Institute, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China zhy3331a@shsmu.edu.cn lvwei@sinh.ac.cn lihecheng2000@hotmail.com zhang…
  • Department of Thoracic Surgery, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China zhy3331a@shsmu.edu.cn lvwei@sinh.ac.cn lihecheng2000@hotmail.com zhangpengdyx@163.com.

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Project of MOST, China
  • Natural Science Foundation of Shanghai Municipality

Zitieren

APA

Zhou, H., Li, J., Mei, S., Zhang, M., Zhao, H., Yan, K., Cheng, Y., Zhou, Q., Zheng, P., Liu, Y., Zhang, P., Li, H., Lu, W., & Zhang, Y. (2026). Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal for ImmunoTherapy of Cancer, 14(2), e013636. https://doi.org/10.1136/jitc-2025-013636

Vancouver

Zhou H, Li J, Mei S, Zhang M, Zhao H, Yan K, et al. Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting. Journal for ImmunoTherapy of Cancer. 2026;14(2):e013636. doi:10.1136/jitc-2025-013636

BibTeX
@article{Zhou2026,
  author = {Zhou, Haoyue and Li, Jinmei and Mei, Song and Zhang, Meiyu and Zhao, Haochen and Yan, Kepeng and Cheng, Yumeng and Zhou, Qunmin and Zheng, Pan and Liu, Yang and Zhang, Peng and Li, Hecheng and Lu, Wei and Zhang, Yan},
  title = {Specific depletion of TIGIT high CD226 − clonally expanded intratumoral Tregs defines safe and effective TIGIT targeting},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  volume = {14},
  number = {2},
  pages = {e013636},
  doi = {10.1136/jitc-2025-013636}
}
Kostenlos starten →